Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Harper Hubbeling"'
Autor:
Satoshi Yoda, Wafa Malik, Adam Langenbucher, Justin F. Gainor, Sai-Hong Ignatius Ou, Kylie Prutisto-Chang, Ramin Sakhtemani, Jennifer L Peterson, Aaron N. Hata, Alexander Drilon, Andrew Do, Jessica J. Lin, Adam J. Schoenfeld, Viola W. Zhu, Ted William Johnson, Jochen K. Lennerz, Lecia V. Sequist, Noura J. Choudhury, Ibiayi Dagogo-Jack, Subba R. Digumarthy, Christina Falcon, Charlotte E. Lee, Alice T. Shaw, Michael S. Lawrence, Beow Y. Yeap, Jennifer S. Temel, Harper Hubbeling
Publikováno v:
Clin Cancer Res
Purpose: Current standard initial therapy for advanced, ROS proto-oncogene 1, receptor tyrosine kinase fusion (ROS1)-positive (ROS1+) non–small cell lung cancer (NSCLC) is crizotinib or entrectinib. Lorlatinib, a next-generation anaplastic lymphoma
Autor:
Beow Y. Yeap, Jochen K. Lennerz, Harper Hubbeling, Rebecca J. Nagy, Jennifer Ackil, Jessica J. Lin, Marguerite Rooney, Aaron N. Hata, Emily Chin, Anna F. Farago, Alice T. Shaw, Justin F. Gainor, Richard B. Lanman, Ibiayi Dagogo-Jack
Publikováno v:
Clinical Cancer Research. 25:6662-6670
Purpose: Acquired resistance to next-generation ALK tyrosine kinase inhibitors (TKIs) is often driven by secondary ALK mutations. Here, we investigated utility of plasma genotyping for identifying ALK resistance mutations at relapse on next-generatio
Autor:
Justin F. Gainor, William A. Mehan, Emily Schapira, Alice T. Shaw, Jessica J. Lin, Kelly Goodwin, Nora Horick, Kevin S. Oh, Helen A. Shih, Harper Hubbeling
Publikováno v:
Journal of Thoracic Oncology. 13:550-558
Introduction Intracranial metastases are a common cause of morbidity and mortality in patients with advanced NSCLC, and are frequently managed with radiation therapy (RT). The safety of cranial RT in the setting of treatment with immune checkpoint in
Autor:
James S. Hardwick, Alice T. Shaw, Anna F. Farago, Aaron N. Hata, Lorin A. Ferris, Diane Tseng, Katherine Schultz, Beow Y. Yeap, Luc Friboulet, Justin F. Gainor, Satoshi Yoda, Donghui Huang, Leila Dardaei, Zofia Piotrowska, Ibiayi Dagogo-Jack, A. John Iafrate, Jessica J. Lin, Harper Hubbeling, Mari Mino-Kenudson
Publikováno v:
JCO Precision Oncology. :1-13
Purpose The ROS1 tyrosine kinase is activated through ROS1 gene rearrangements in 1% to 2% of non–small-cell lung cancers (NSCLCs), which confer sensitivity to treatment with the anaplastic lymphoma kinase (ALK)/ROS1/mesenchymal-epithelial transiti
Autor:
Alice T. Shaw, Luc Friboulet, Daria Timonina, Benjamin J. Burke, Krystina E. Kattermann, Justin F. Gainor, Jeffrey A. Engelman, Amanda K. Riley, A. John Iafrate, Jochen K. Lennerz, Adam Langenbucher, Sergei Timofeevski, Aaron N. Hata, Leila Dardaei, Cyril H. Benes, Lorin A. Ferris, Jessica J. Lin, Kylie Prutisto-Chang, Ted William Johnson, Harper Hubbeling, Rebecca S. Heist, Ibiayi Dagogo-Jack, Mari Mino-Kenudson, Satoshi Yoda, Michael S. Lawrence
Publikováno v:
Cancer Discovery
The cornerstone of treatment for advanced ALK-positive lung cancer is sequential therapy with increasingly potent and selective ALK inhibitors. The third-generation ALK inhibitor lorlatinib has demonstrated clinical activity in patients who failed pr
Autor:
Andrzej Niemierko, Justin F. Gainor, William L. Hwang, Emily Schapira, Katie L. Hwang, Florence K. Keane, Harper Hubbeling
Publikováno v:
JAMA oncology. 4(2)
This cohort study evaluates the clinical outcomes in patients with metastatic lung cancer treated with PD-1/PD-L1 inhibitors and thoracic radiotherapy.